ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Sales 2024 * | 622M 49.59B | Sales 2025 * | 774M 61.73B | Capitalization | 6.12B 488B |
---|---|---|---|---|---|
Net income 2024 * | -573M -45.68B | Net income 2025 * | -494M -39.38B | EV / Sales 2024 * | 9.67 x |
Net cash position 2024 * | 111M 8.84B | Net Debt 2025 * | 218M 17.4B | EV / Sales 2025 * | 8.19 x |
P/E ratio 2024 * |
-10.6
x | P/E ratio 2025 * |
-12.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 30/06/12 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 30/04/00 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 02/02/14 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Joan Herman
BRD | Director/Board Member | 70 | 09/06/19 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+44.64% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |